Colecalciferol

胆骨化醇

Report date: 2026/05/14 20:00:28
NME

Base Information

Drug NameColecalciferol
Drug Alias Name维生素D3CholecalciferolDelta-DCalciolColecalciferolum +[11] 
ClassificationSmall molecules > Amino acid supplement, Lipids and Vitamins
Mechanisms of ActionVitamin D receptor agonists
TargetsVitamin D receptor
Therapy Area/IndicationsRejection of renal transplantationCoronavirus Disease 2019 (COVID-19)Metastatic breast cancer +[149] 
Global Approved IndicationsHypoparathyroidismVitamin D DeficiencyFamilial Hypophosphatemic Rickets
Approved Indications in ChinaVitamin D Deficiency
Original Approved Country/TerritoryCanada
Original Approved Date1985/01/01
Country/TerritoryBelgiumAfghanistanCanada +[34] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesN/A
China Registration ClassN/A

Develop Information

Active CompaniesKing Faisal Specialist Hospital And Research CenterDana-Farber Cancer InstituteDiabetes Research Institute Foundation +[29] 
Inactive CompaniesUniversity Of North Texas Health Science CenterUtah State UniversityAugusta University +[99] 
Active IndicationsCoronavirus Disease 2019 (COVID-19)Neuroinflammatory DiseasesCognition Disorders +[44] 
Inactive IndicationsRejection of renal transplantationMetastatic breast cancerSolid tumours +[105] 

Other Information

ATC CodeA11CC05
Related LinksWikipediaDrugBankKEGG